Tuebingen, Germany ; Houston, Texas; and Cambridge, Mass., June 7, 2022 – Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc.